About a week after announcing it was eyeing strategic alternatives, including a merger or acquisition, Tempest Therapeutics disclosed it is cutting about 80% of its workforce. The Brisbane, California–based biotech is letting go of 21 of its 26 full-time employees effective April 30, according to an April 18 SEC filing. The company expects key staff will transition to consulting agreements.
